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ARTICLE OPEN
MTBVAC vaccination protects rhesus macaques against
aerosol challenge with M. tuberculosis and induces immune
signatures analogous to those observed in clinical studies
Andrew D. White 1✉, Laura Sibley1, Charlotte Sarfas1, Alexandra Morrison1, Jennie Gullick1, Simon Clark1, Fergus Gleeson2,
Anthony McIntyre 2, Cecilia Lindestam Arlehamn 3, Alessandro Sette3, Francisco J. Salguero 1, Emma Rayner1, Esteban Rodriguez4,
Eugenia Puentes4, Dominick Laddy5, Ann Williams1, Mike Dennis1, Carlos Martin 6 and Sally Sharpe1
A single intradermal vaccination with MTBVAC given to adult rhesus macaques was well tolerated and conferred a significant
improvement in outcome following aerosol exposure to M. tuberculosis compared to that provided by a single BCG vaccination.
Vaccination with MTBVAC resulted in a significant reduction in M. tuberculosis infection-induced disease pathology measured using
in vivo medical imaging, in gross pathology lesion counts and pathology scores recorded at necropsy, the frequency and severity of
pulmonary granulomas and the frequency of recovery of viable M. tuberculosis from extrapulmonary tissues following challenge.
The immune profiles induced following immunisation with MTBVAC reflect those identified in human clinical trials of MTBVAC.
Evaluation of MTBVAC- and TB peptide-pool-specific T-cell cytokine production revealed a predominantly Th1 response from poly-
(IFN-γ+TNF-α+IL2+) and multi-(IFN-γ+TNF-α+) functional CD4 T cells, while only low levels of Th22, Th17 and cytokine-producing
CD8 T-cell populations were detected together with low-level, but significant, increases in CFP10-specific IFN-γ secreting cells. In
this report, we describe concordance between immune profiles measured in clinical trials and a macaque pre-clinical study
demonstrating significantly improved outcome after M. tuberculosis challenge as evidence to support the continued development
of MTBVAC as an effective prophylactic vaccine for TB vaccination campaigns.
npj Vaccines (2021)6:4 ; https://doi.org/10.1038/s41541-020-00262-8
INTRODUCTION
Tuberculosis (TB) is the leading cause of death of humans from a
single infectious agent worldwide. It is estimated that 10 million
people fell ill with TB in 2018 and TB was responsible for 1.5
million deaths1. In total, 1.7 billion people are estimated to be
latently infected with TB, and 10% of these individuals are at high
risk of relapsing with active disease during their lifetime. The
emergence of multidrug-resistant and extensively drug-resistant
strains of Mycobacterium tuberculosis (M. tuberculosis), together
with the geographical overlap between the HIV and TB epidemics,
mean that there is an urgent need for better control of TB.
Vaccination is the most effective way to control any infectious
disease; however, the only vaccine currently available against TB,
Mycobacterium bovis bacillus Calmette-Guérin (BCG), whilst
effective against severe manifestations of infant tuberculosis2, is
only partially effective against adult pulmonary TB3.
Non-human primate (NHP) models provide the most relevant
pre-clinical models of human disease and play a critical role in
vaccine development. Macaque models of M. tuberculosis have
been established4–7 within which BCG has been shown to confer
low-level efficacy against infectious challenge8, thus providing an
arena in which new vaccine regimens could demonstrate superior
efficacy relative to both unvaccinated or BCG-vaccinated indivi-
duals. Immune signatures that associate with an improved
outcome of challenges have been identified in macaque
studies8–10, and because of the similarities between the macaque
and human immune systems and the response to TB infection11, it
is considered that such immune signatures would be relevant to
humans. Thus far it has not been possible to verify this assumption
or validate putative correlates of protection because there have
been insufficient parallels between TB vaccine clinical trials and
pre-clinical vaccine efficacy studies showing improved outcome in
the non-human primate model for comparisons to provide
meaningful data.
MTBVAC is a live-attenuated strain of M. tuberculosis derived
from a clinical isolate belonging to modern lineage 4, which is
known to have a worldwide pattern of distribution. MTBVAC was
designed to stimulate specific host immune responses mimicking
natural TB infection without causing disease through rational
attenuation by deletion of the major virulence genes phoP and
fadD2612. MTBVAC contains all antigens present in M. tuberculosis,
including those contained in the RD1 region, that are absent from
BCG and have been associated with improved protection in
animal models13. Since 2012, MTBVAC has been the only live-
attenuated M. tuberculosis-based vaccine candidate in clinical
trials. The safety and immunogenicity of MTBVAC were demon-
strated in adults in a Phase Ia trial14, and in neonates by a Phase Ib
trial conducted in an endemic country, which showed that
MTBVAC is as safe as BCG and more immunogenic15. MTBVAC is
now in Phase IIa dose-defining trials in both adolescents and
newborns in South Africa (NCT02933281 and NCT03536117).
Furthermore, data from pre-clinical testing in small animal models
suggest that MTBVAC vaccination is safe, immunogenic and has
the potential to enhance protection against experimental M.
tuberculosis challenge relative to BCG12,16,17. Evaluation of the
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immunogenicity and efficacy of MTBVAC in the macaque M.
tuberculosis challenge model would provide data to accelerate and
assist product development pathway decisions to move to efficacy
trials.
This study aimed to determine the protective efficacy against
low-dose aerosol challenge with M. tuberculosis conferred by a
single intradermal vaccination with MTBVAC to rhesus macaques;
to characterise the immune response induced following vaccina-
tion and to compare the immune signatures defined in macaques
with those defined in MTBVAC immunised humans.
RESULTS
Vaccination
All animals in the study showed the weight gain profiles expected
in normal healthy animals during the period prior to challenge
and were unperturbed by vaccination (Supplementary Fig. 1A).
Body temperature, erythrocyte sedimentation rate (ESR) and red
cell haemoglobin concentration level remained within the normal
range for the species during the period between vaccination and
challenge in all individuals (Supplementary Fig. 1B–D). Mild
induration and erythema occurred at the site of immunisation in
all the animals that received an intradermal vaccination with BCG
and in five of the eight macaques that received intradermal
vaccination with MTBVAC. The skin reactions induced were
comparable in size and resolved within six weeks after MTBVAC
vaccination and between six and fourteen weeks after BCG
(Supplementary Fig. 1E).
M. tuberculosis exposure and challenge outcome
Twenty-one weeks after vaccination, the macaques were exposed
to aerosols containing an average of 27 CFU (range 14–30 CFU) M.
tuberculosis Erdman providing an estimated median retained dose
in the lung of 4 CFU. To monitor disease development, CT scans
were collected 3, 8, 12 and 16 weeks after aerosol exposure and
disease burden evaluated using a quantitative score system based
on the extent and features of the disease visible. Whilst disease
burden was comparable across groups three weeks after
challenge, at week 8, significantly improved outcomes were
observed in the two vaccinated groups relative to the unvacci-
nated group (Fig. 1a–d) (MTBVAC group: total CT score: P= 0.0044,
lung CT score: P= 0.0050, number of pulmonary nodules: P=
0.0008, pneumonia burden: P= 0.0014; BCG group: total CT score:
P= 0.0238, lung CT score: P= 0.0286, number of pulmonary
nodules: P= 0.0068, pneumonia burden: P= 0.0039). At week 12
(Fig. 1f–i), the disease burden in the MTBVAC group remained
significantly lower than in both the unvaccinated group (total CT
score: P= 0.0208, lung CT score: P= 0.0249, pneumonia burden:
P= 0.0182), and the BCG group (total CT score: P= 0.0073, lung
CT score: P= 0.0407, pneumonia burden: P= 0.0350). A trend for
reduced incidence of lymph node involvement, identified as
enlargement and/or necrosis, was seen in the group that received
MTBVAC (Fig. 1j) in comparison to that seen in the groups that
received BCG, or remained unvaccinated.
During the post-M. tuberculosis-exposure period, one of the
BCG-vaccinated animals and three of the unvaccinated animals
showed changes in behaviour and clinical parameters (weight
loss, anaemia or dyspnoea) consistent with progression of the
tuberculosis-induced disease that met humane endpoint criteria
and was euthanized ahead of the planned end of the study. None
Fig. 1 Study schedule and in vivo CT imaging. a Diagram showing the week in which clinical examinations (open circle), blood sample
collections (shaded circle), CT scan collection, the aerosol challenge with M. tuberculosis and necropsy (black circle) were conducted relative to
vaccination. Disease burden development quantified from CT scans reflects scores derived for total disease burden (b), pulmonary disease
burden (c), pneumonia (d) and the number of TB-induced nodules in the lung (e) from CT scans collected eat weeks 3, 8, 12 and 16 after
challenge with M. tuberculosis. Box plots show group median values +/− IQR with minimum and maximum values indicated by box whiskers. f
Incidence of lymph node disease across the 16-week study period. Non-parametric Mann–Whitney U tests were used for comparison between
groups with unadjusted results reported as: *P ≤ 0.05; **P ≤ 0.005.
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of the animals in the MTBVAC group, or the remaining animals in
the BCG and unvaccinated groups, showed adverse behavioural or
premortem clinical indicators at the time of termination. The
proportion of, and time at which, animals progressed to meet pre-
defined humane endpoint criteria were plotted and vaccination
groups compared using the log-rank test (Fig. 2a). This analysis
indicated trends for improved control of disease progression
during the first 16 weeks following TB infection in animals that
had been vaccinated with BCG, or MTBVAC, in comparison to the
unvaccinated group (MTBVAC vs unvaccinated: P= 0.063, BCG vs
unvaccinated: P= 0.23).
At the end of the study, a range of approaches were applied to
measure the level of tuberculosis-induced disease burden.
Changes in body weight, measured at necropsy relative to the
peak weight measured during the post-challenge period, were
apparent in unvaccinated animals and animals that had been
removed from the study due to disease progression criteria (Fig.
2b). TB-associated, pathological changes were quantified at
necropsy using a gross pathology score system (Fig. 2c) and
revealed that gross pathology was significantly reduced in the
group that received MTBVAC compared to macaques vaccinated
with BCG (total pathology score: P= 0.005; lung pathology score:
P= 0.021; disseminated pathology score: P= 0.004), and unvacci-
nated macaques (total pathology score: P= 0.015; lung pathology
score: P= 0.003; disseminated pathology score: P= 0.003).
Pulmonary disease burden measured by the manual counting
of both discrete and coalesced lesions from serial sections
revealed significantly fewer macroscopic lesions in the lungs from
the MTBVAC-vaccinated group compared to either the BCG-
vaccinated group (P= 0.04) or the unvaccinated group (P= 0.025)
(Fig. 2d). Microscopic granulomas were identified in H&E-stained
sections prepared from representative lung lobe and extrapul-
monary tissue samples, classified into six stages and counted.
Granulomas were most prevalent in the pulmonary tissues from
the unvaccinated group and significantly less abundant in the
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Fig. 2 Tuberculosis-induced disease burden. a Kaplan–Meier plot showing the development of progressive disease to a level that met
humane endpoint criteria in vaccinated and unvaccinated macaques after challenge with M. tuberculosis. Unadjusted P values from log-rank
comparisons are shown. b Change in body weight expressed as a percentage of the peak weight measured during the post-challenge study
period. c Total, pulmonary and disseminated (spleen, liver, kidneys) tuberculosis-induced disease burden measured using a gross pathology
score system. d The number of macroscopic lesions in the lungs following serial sectioning. e Total number of granulomas (stage I–VI
combined) identified in the lung from representative H&E-stained sections. f Total number of granulomas (stage I–VI combined) identified in
the lung from representative H&E-stained sections where stacked bars indicate the number of granulomas at each stage I–VI and the
combined total within each experimental group. g Total number of granulomas (stage I–VI combined) identified in the extrapulmonary tissues
(spleen, liver, kidneys) from representative H&E-stained sections. h The proportion of tissue samples cultured from which M. tuberculosis was
isolated (>LLOD: CFU value greater than the lower limit of detection of the assay; LLOD: value recorded as the lower limit of detection of the
assay). i Bacterial burden determined in lung-associated lymph nodes (LALN) and extrapulmonary tissues. The colour and symbol coding per
individual is consistent throughout and between figures. Upside down triangular symbols indicate animals in which disease progressed to
meet humane endpoint criteria. Non-parametric Mann–Whitney U tests were used for group-wise comparisons of pathology scores,
granuloma/lesion counts and viable CFU counts recovered from tissues, with unadjusted results reported as: *P ≤ 0.05; **P ≤ 0.01. Χ2 tests were
used to compare the proportion of tissues with viable M. tuberculosis CFU counts above or below the LLOD of the assay between vaccination
groups and Cochran–Armitage method Χ2 tests to compare granuloma stage scores between groups, unadjusted results are reported as *P ≤
0.05; **P ≤ 0.01; ***P ≤ 0.001.
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the combined number of each type of granuloma identified in the
sections examined from pulmonary (Fig. 2f) and extrapulmonary
(Fig. 2g) tissues revealed granulomas of all stages were observed
in all groups, but the number and distribution varied amongst
groups. Type V and type VI granulomas, representing more
advanced lesion development, were most numerous in the
unvaccinated group making up approximately half of the
granulomas observed in tissue sections; by contrast, type V and
type VI granulomas made up a smaller proportion of the
granulomas observed in the group that received MTBVAC. The
number of acid-fast bacilli (AFB) associated with each granuloma
increased alongside the development of granulomas. AFB were
not observed within type I or II granulomas collected from any of
the macaques and only at low numbers in granulomas of type III,
IV and V. The majority of AFB were found within the necrotic cores
of type VI granulomas. AFB were most prevalent in granulomas
from the unvaccinated group and less abundant in those from
vaccinated groups, with the fewest counted in those from the
MTBVAC-vaccinated group (Supplementary Table 1).
The spleen, kidneys, liver and lung-associated lymph nodes
(LALN) were sampled for the presence of viable M. tuberculosis
post-mortem. Bacteria were cultured from significantly fewer of
the samples collected from the macaques given MTBVAC than
from those collected from the BCG-vaccinated group (P= 0.011)
or the unvaccinated control group (P= 0.003) (Fig. 2h). While the
bacterial burden measured in the LALN was similar across all the
study groups, the burden measured in the extrapulmonary tissues
collected from MTBVAC-vaccinated (P= 0.0337) and the BCG-
vaccinated animals was reduced compared to that measured in
tissues from unvaccinated animals (Fig. 2i).
Immune responses following vaccination and infection
The mycobacterium-specific IFN-γ response induced by vaccina-
tion and M. tuberculosis challenge was measured using an ex vivo
ELISpot assay applied at 2-week intervals through the study (Fig.
3a). In the period before the challenge, PPD-specific IFN-γ spot
forming unit (SFU) frequencies significantly increased above the
threshold in all macaques that received vaccinations with BCG or
MTBVAC (BCG: P= 0.0002; MTBVAC: P= 0.0002). The peak PPD-
specific response occurred four weeks after vaccination in the
MTBVAC group and 2 weeks later in the BCG-vaccinated group at
week 6. Twenty weeks after vaccination and 1 week before
challenge with M. tuberculosis, PPD-specific IFN-γ SFU frequencies
measured in the vaccinated groups were significantly higher than
the levels measured in the unvaccinated group (BCG: P= 0.0006;
MTBVAC: P= 0.0019). CFP10-specific IFN-γ SFU frequencies
exceeding the assay threshold between vaccination and challenge
were only detected in the MTBVAC group and consequently, the
response was significantly higher than those in the BCG-
vaccinated (P= 0.0011) and the unvaccinated groups (P=
0.0033), with the largest responses seen between 6 and 10 weeks
(Fig. 3b). During the same period between vaccination and
challenge, ESAT6-specific SFU frequencies did not increase above
background levels in any of the test groups. Following exposure to
M. tuberculosis, reduced frequencies of PPD, CFP10 and ESAT6-
specific SFU were seen in the MTBVAC and BCG-vaccinated groups
relative to the unvaccinated group, with the differences reaching
significance for PPD and ESAT6 in the MTBVAC-vaccinated group
(PPD: P= 0.0030; ESAT6: P= 0.0030) and for PPD and CFP10 in the
BCG-vaccinated group (PPD: P= 0.0104; CFP10: P= 0.0070). Four-
teen weeks after the challenge, the MTBVAC group showed
significantly lower levels of PPD-, CFP10- and ESAT6-specific SFU
in the periphery than those recorded in the BCG-vaccinated group
(PPD: P= 0.0379; CFP10: P= 0.0148; ESAT6: P= 0.0148) which
could be interpreted as better control of the M. tuberculosis
infection.
Multiparameter flow cytometry assays were applied to explore
the phenotype and functional profile of the cellular immune
response. Application of intracellular cytokine staining to measure
antigen-specific cytokine production revealed increased frequen-
cies of multifunctional CD4 T-cells producing IFN-γ, IL-2 and TNF-α
(polyfunctional), or IFN-γ and TNF-α, in animals that received BCG
or MTBVAC, with the frequency of cytokine-producing cells
reaching significance above pre-vaccination levels from four
weeks after vaccination (Fig. 4a, b and Supplementary Fig. 2A,
B). Cytokine-producing CD4 T-cell populations remained
unchanged in the unvaccinated group consistent with the lack
of experimental intervention applied to this group at this stage of
the experiment (Fig. 4c and Supplementary Fig. 2C). Comparison
of multifunctional T-cell frequencies between the vaccination
groups indicated that significantly higher frequencies of CD4 T-
cells producing IFN-γ, IL-2 and TNF-α (Fig. 4d); or IFN-γ and TNF-α
(comparative plot not shown) simultaneously were present in the
BCG- and MTBVAC-vaccinated groups relative to the unvaccinated
animals at weeks 4, 8, 12 and 18. Changes in the frequency of
antigen-specific CD4 T-cells producing IL-17 or IL-22 were not
detected following vaccination and differences were not apparent
between the vaccination groups (Fig. 4e, f), indicating that both
BCG and MTBVAC vaccination induced a predominantly Th1 CD4
T-cell response. Vaccination-induced cytokine-producing CD8 T-
cell populations were detected at a low frequency relative to the
CD4 T-cell subsets and generally did not increase significantly
above pre-vaccination levels (Supplementary Figs. 3 and 4).
Similarly, potential vaccination-induced changes in the frequency
of innate lymphoid cells were explored by quantification of
mucosal-associated invariant T cells (MAIT’s) and natural killer (NK)
cell subsets. However, MAIT cell frequencies detected in BCG,
MTBVAC and unvaccinated groups remained at low frequency
(group medians below 1% of the total T-cell population) following
vaccination (Supplementary Fig. 5A), and NK cell populations
(identified by the pattern of CD56 and CD16 expression) did not
differ significantly at any time point in comparison to pre-
vaccination levels or between the vaccination groups (Supple-
mentary Fig. 5B). Furthermore, cytokine production from the NK
cell population as a whole (regardless of CD56 and CD16
expression) was assessed (Supplementary Fig. 5C–H), but sig-
nificant differences were not detected in the total frequency of NK
cells producing IFN-γ, IL-2, TNF-α, IL-17 or IL-22 following MTBVAC
or BCG vaccination in comparison to pre-vaccination levels.
Antigen-specific cytokine production by γδ T-cell populations
was found to primarily consist of TNF-α and IL-17 producing cells,
with higher frequencies detected in response to stimulation with
MTBVAC rather than pooled M. tuberculosis-derived peptides
(Supplementary Figs 6 and 7). Trends for a vaccine-induced
increase in the frequency of cytokine-producing γδ T-cell
populations were apparent in both the BCG and MTBVAC-
vaccinated groups; however, these responses failed to reach
significance above pre-vaccination levels (Supplementary Figs 6
and 7). Comparison of IL-17-producing γδ T-cell frequencies
between groups at each time point following vaccination
(Supplementary Fig. 6) indicated a trend for increased production
of IL-17 at weeks 4 and 8 following MTBVAC vaccination, whereas
by weeks 12 and 18 greater frequencies were measured in the
BCG-vaccinated group. Despite these trends, the differences
measured between the vaccination groups did not reach statistical
significance. Nevertheless, as a large proportion of the γδ T-cell
population produced antigen-specific IL-17 following vaccination,
which was in contrast to the low frequency of IL-17-producing
CD4 and CD8 T cells, this indicates a potentially important role for
the γδ T-cell subset in the production of this important
immunomodulatory cytokine.
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DISCUSSION
Intradermal vaccination with MTBVAC was well tolerated by adult
rhesus macaques and conferred a significant improvement in
outcome following aerosol exposure to M. tuberculosis compared
to that provided by BCG vaccination. Statistically significant
differences in disease burden development were demonstrated
between groups measured using a scoring system applied to CT
scan images. This approach revealed the disease burden in the
MTBVAC group to be significantly reduced compared to that in
the unvaccinated control group 8 weeks after challenge and
significantly reduced in comparison to the BCG-vaccinated group
by week 12. This finding was reflected in the results of the
analyses applied at the end of the study schedule, 16 weeks after
challenge, when measures based on the assessment of macro-
scopic and microscopic pathology and bacterial burden verified
an improved outcome after challenge in the MTBVAC-vaccinated
group relative to the BCG-vaccinated and the unvaccinated
groups. Furthermore, after the challenge, higher levels of CFP10
and ESAT6-specific IFN-γ-secreting cells were detected in the
unvaccinated relative to the vaccinated groups with the lowest
levels present in the MTBVAC group. The association between
increased frequencies of CFP10 and ESAT6-specific responses
post-challenge with the poorer post-challenge outcome is
consistent with other reports and suggests that the frequency of
responses to these diagnostic antigens provides a biomarker
reflective of disease progression and antigen load. The rhesus
macaque provides a stringent model, in which only a few vaccines
have conferred significant improvements in outcome after M.
tuberculosis challenge8–10,18–20 and only one other new TB vaccine
has afforded significantly superior protection compared to
intradermally delivered BCG19. Taken together, these data support
the continued development of MTBVAC as a more effective
prophylactic vaccine for TB vaccination campaigns.
The immune profiles induced following immunisation with
MTBVAC reflect those identified in human clinical trials14,15,17.
Evaluation of MTBVAC- and TB peptide-pool-specific T-cell
cytokine production revealed a predominantly Th1 response
profile from poly- (IFN-γ+TNF-α+IL2+) and multi- (IFN-γ+TNF-α+)
functional CD4 T cells, while only low levels of Th22, Th17 and
cytokine-producing CD8 T-cell populations were detected. As in
clinical trials, these profiles were similar in profile and scale to
those identified after BCG vaccination; although differences in
antigen recognition were detected that reflect protective immu-
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Fig. 3 Immune response to vaccination and challenge. The frequency of M. tuberculosis antigen-specific IFN-γ-secreting cells induced
following BCG vaccination and challenge measured by ELISpot (a). Top row: PPD-specific response profiles, middle row: ESAT6-specific
response profiles, bottom row: CFP10-specific response profiles. Left: response profiles in the MTBVAC-vaccinated group; middle: response
profiles in the BCG-vaccinated group; right: response profiles in the unvaccinated group. Vaccination with MTBVAC, or BCG indicated by the
dotted line, and aerosol exposure to M. tuberculosis indicated by the dashed line at week 21. Comparison of the CFP10-specific IFN-γ response
measured by ELISpot induced following vaccination with BCG or MTBVAC determined by analysis of the area under the response curve
between week 2 and 20 after vaccination with group comparison made using Mann–Whitney between groups **P ≤ 0.005 (b). All line graphs
show individual response (circular symbol) and Group median response (solid line). The colour and symbol coding per individual is consistent
throughout and between figures. Upside down triangular symbols indicate animals in which disease progressed to meet humane endpoint
criteria. The assay threshold (mean of pre-vaccination values plus 1.5× standard deviation) is indicated by a horizontal dotted line (PPD:
119 spot forming units (SFU) per million cells; ESAT6: 40 SFU per million cells; CFP10: 28 SFU per million cells).
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included the detection of low-level CFP10-specific IFN-γ responses
following MTBVAC, but not BCG, vaccination. This is analogous to
the findings of Aguilo et al.17, who have demonstrated a link
between MTBVAC-induced CFP10 and ESAT6-specific IFN-γ secre-
tion and improved protection against M. tuberculosis challenge in
the C3H/HeNRj mouse strain, an improvement that was negated
when mice were vaccinated with the ESAT6 and CFP10 ablated
MTBVAC-ΔE6C10 construct. Low-level, but significant, increases in
CFP10-specific IFN-γ-secreting cells have also been detected in
MTBVAC-vaccinated human volunteers; although, in contrast to
murine studies, ESAT6-specific cytokine production did not
increase significantly in this population14,17. This profile of antigen
specificity was mirrored directly by the cellular immune responses
measured in macaques where significant increases in CFP10-, but
not ESAT6-, specific IFN-γ secreting cells were detected following
MTBVAC vaccination. This not only provides further evidence that
a low-level CFP10-specific immune response is a key feature of the
MTBVAC-induced cell-mediated response but is also a validation
that the immunogenicity profiles measured in macaques are
representative of immune signatures observed in humans. This
concordance between immune profiles measured in clinical trials
and a macaque pre-clinical assessment of a novel TB vaccine
candidate demonstrating significantly improved outcome after M.
tuberculosis challenge is a promising indication that the improved
protection provided by MTBVAC vaccination to macaques and
mice will translate to the human population.
METHODS
Experimental animals
Twenty-four male and female rhesus macaques (Macaca mulatta) of Indian
origin aged between 4.2 and 5.2 years of age were sourced from an
established, characterised, closed UK breeding colony. Compatible social
groups were housed in accordance with Home Office (UK)21 and NC3Rs
guidelines22 in cages with high-level observation balconies, extensive
environmental stimulation and provided with a wide range of dietary
enrichment23. Animal procedures and study designs were approved by the
Establishment of Animal Welfare and Ethical Review Committee and
authorised under a UK Home Office project licence. Prior to challenge with
M. tuberculosis macaques were housed in cages approximately 2.5-m high
by 4-m long by 2-m deep, constructed with high-level observation
balconies and with a floor of deep litter to allow foraging. Following the
challenge, animals were transferred to banks of cages placed in directional
airflow containment systems that allowed group housing and environ-
mental control whilst providing a continuous, standardised inward flow of
fully conditioned fresh air identical for all groups. Additional environmental
enrichment was afforded by the provision of toys, swings, feeding puzzles
and DVDs for visual stimulation. In addition to standard old-world primate
pellets, the diet was supplemented with a selection of fresh vegetables and
fruit. For each procedure, sedation was applied by intramuscular injection
with ketamine hydrochloride (10mg/kg) (Ketaset, Fort Dodge Animal
Health Ltd, Southampton, UK). None of the animals had been used
previously for experimental procedures, and each socially compatible
group was randomly assigned to study treatment. Prior to study
enrolment, previous exposure to mycobacterial antigens was assessed
using an IFN-γ ELISPOT (MabTech, Nacka. Sweden) to detect responses to
Fig. 4 M. tuberculosis peptide-specific CD4 T-cell cytokine secretion profiles measured by whole blood intracellular cytokine staining. Box
plots show the vaccination group median frequency of CD4 T-cells producing combinations of the cytokines IFN-γ, IL-2 and TNF-α (a–d); IL-17
(e) or IL-22 (f) +/− IQR with minimum and maximum values indicated by box whiskers. Cytokine production was measured at weeks prior to
(−1), and following (4, 8, 12 and 18) BCG or MTBVAC vaccination. Significant differences between pre- and post-vaccination values (Wilcoxon
signed-rank) and between groups (Mann–Whitney U test) are indicated by bars and asterisks: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (all P values are
unadjusted for multiple comparisons). Frequencies measured in individual animals are represented by dots.
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tuberculin-PPD (SSI, Copenhagen, Denmark), and pooled 15-mer peptides
of ESAT6 and CFP10 (Peptide Protein Research LTD, Fareham, U.K.).
Vaccination
The vaccination schedule relative to the aerosol challenge is shown in Fig.
1a. The sample size for the experiment was determined using total
pathology score as the primary efficacy readout and was powered to
detect a nine-point reduction (arbitrary units) with a power of 80% and an
α of 0.05. Eight of the macaques were immunised by intradermal (ID)
injection in the upper left arm with 100 μl of BCG vaccine, Danish strain
1331 (1st WHO reference reagent, NIBSC, UK), the second group of eight
macaques received an ID vaccination with 100 μl of MTBVAC (Biofabri,
Spain) and the remaining eight animals were left untreated as a negative
control group. The BCG and MTBVAC vaccines were prepared for
intradermal administration according to the manufacturer’s instructions
for administration to humans. One ml of Sautons diluent was added to a
vial of BCG vaccine to give a suspension of BCG at an estimated
concentration of between 2 and 8 × 106 CFU/ml and 1ml of sterile water
was added to MTBVAC to give a concentration of 3–17 × 106 CFU. Due to
differences in vaccine diluent solutions, it was not possible to deliver a
mock vaccination to animals in the unvaccinated control group.
Vaccinations were administered within 1 h of vaccine reconstitution. Plate
culture of residual vaccine confirmed the viability of the BCG and MTBVAC
vaccines, and the mean average administered dose of each vaccine was
calculated to be 1.2 × 106 (SD 3.4 × 104) CFU and 8.2 × 105 (SD 3.9 × 104)
CFU for BCG and MTBVAC respectively. The injection sites were monitored
for local reactions after vaccination with BCG or MTBVAC such that
reactions were measured and assessed.
M. tuberculosis challenge strain
The Erdman K01 stock (HPA-Sept 2011) used for the challenge was
prepared from stocks of the M. tuberculosis Erdman strain K01 (BEI
Resources). A stock suspension was initially prepared from a 5-ml
bacterial starter culture originally generated from colonies grown on
Middlebrook 7H11 supplemented with oleic acid, albumin, dextrose and
catalase (OADC) selective agar (BioMerieux, UK). A liquid batch culture
was then grown to logarithmic growth phase in 7H9 medium (Sigma-
Aldrich, UK) supplemented with 0.05% (v/v) Tween 80 (Sigma-Aldrich,
UK). Aliquots were stored at −80 °C. The concentration of colony-
forming units (CFU)/ml in the stock suspension was determined from
thawed aliquots by enumeration of CFU cultured on Middlebrook 7H11
OADC selective agar.
Aerosol exposure
Twenty-one weeks after vaccination, all animals were challenged by
exposure to aerosols of M. tuberculosis, as previously described24,25. Mono-
dispersed bacteria in particles were generated using a three-jet Collison
nebuliser (BGI) and, in conjunction with a modified Henderson apparatus26,
delivered to the nares of each sedated primate via a modified veterinary
anaesthetic mask. Challenge was performed on sedated animals placed
within a ‘head-out’, plethysmography chamber (Buxco, Wilmington, North
Carolina, USA) to enable the aerosol to be delivered simultaneously with
the measurement of respiration rate and respired volume. The calculations
to derive the presented dose (PD) (the number of organisms that the
animals inhale) and the retained dose (the number of organisms assumed
to be retained in the lung) have been described previously27,28. A nebuliser
concentration was selected to result in a retained dose of approximately
five viable CFU.
Clinical procedures
Full clinical examinations were conducted at 2-week intervals throughout
the study. Macaques were sedated, thoracic radiographs were taken, body
weight and temperature measured and blood samples collected. Red
blood cell (RBC) haemoglobin levels were measured using a HaemaCue
haemoglobinometer (Haemacue Ltd, Dronfield, UK), and ESR was
determined using the Sediplast system (Guest Medical, Edenbridge, UK).
Observed behaviour was monitored for contra-indicators. The time of
necropsy, if prior to the end of the planned study period, was determined
by experienced primatology staff and based on a combination of the
following adverse indicators: depression or withdrawn behaviour, abnor-
mal respiration (dyspnoea), loss of 20% of peak post-challenge body
weight, ESR levels elevated above normal (>20mm), haemoglobin level
below normal limits (<100 g/dL), increased temperature (>41 °C) and
abnormal findings on the thoracic radiographs.
Computed tomography (CT) imaging
CT scans were collected from sedated animals using a 16-slice Lightspeed
CT scanner (General Electric Healthcare, Milwaukee, WI, USA) 3, 8, 12 and
16 weeks after aerosol exposure to M. tuberculosis, as described
previously24. To facilitate full examination of lesions and lymph nodes,
Niopam 300 (Bracco, Milan, Italy), a non-ionic, iodinated contrast medium,
was administered intravenously (IV) at 2 ml/kg body weight. Scans were
evaluated by an expert thoracic radiologist blinded to the animal’s
treatment and clinical status, for the number and distribution across lung
lobes of pulmonary lesions and the presence of disease features, such as
nodular conglomeration, cavitation, consolidation (an indicator of alveolar
pneumonia), a ‘tree-in–bud’ pattern (an indicator of bronchocentric
pneumonia) and lobular collapse. The airways were evaluated for the
occurrence of wall thickening and the presence of bronchocele. The lymph
nodes were assessed for enlargement and the presence of necrosis.
Extrapulmonary tissues, including liver, kidneys and spleen were examined
for the presence of single or multiple foci of disease, cavitation or necrosis.
The disease burden attributable to infection with M. tuberculosis was
scored using a relative scoring system based on the number of lesions
present in lungs, spleen, liver, kidney and lymph nodes, and the presence
and extent of TB-induced structural abnormalities as described pre-
viously23. The scores for consolidation and tree-in-bud were summed to
provide a pneumonia score. The scores attributed to each tissue (lung lobe,
organ, lymph node) were summed to give the total CT score to provide a
measure of pulmonary and extrapulmonary disease burden.
Interferon-gamma (IFN-γ) ELISpot
Peripheral blood mononuclear cells (PBMC) were isolated from heparin
anti-coagulated blood using standard methods. An IFN-γ ELISpot assay was
used to quantify the number mycobacteria-specific IFN-γ-producing T cells
in PBMCs using a human/simian IFN-γ kit (MabTech, Nacka. Sweden), as
described previously24. In brief, 2 × 105 PBMCs were cultured with 10 μg/ml
PPD (SSI, Copenhagen, Denmark) or pools of overlapping 15-mer peptides
spanning CFP10 or ESAT6 (Peptide Protein Research Ltd, Wickham, UK) in
duplicate, or without antigen, in quadruplicate, and incubated for 18 h.
Phorbol 12-myristate (Sigma-Aldrich Dorset, UK) (100 ng/ml) and ionomy-
cin (CN Biosciences, Nottingham, UK) (1 μg/ml) were used as a positive
control. After culture, spots were developed according to the manufac-
turer’s instructions. Plates were scanned, and spots enumerated using a
CTL Immunospot S6 reader and software. Determinations from replicate
tests were averaged, and the data were analysed by subtracting the mean
number of spots in the medium-only control wells from the mean counts
of spots in wells with antigen, or peptide pools, to derive an antigen-
specific spot count. This value was multiplied by a factor of five and
reported as IFN-γ SFU frequency per million PBMCs. A minimum threshold
level of activity was calculated for each mycobacterial antigen by analysis
of the distribution of SFU frequencies quantified prior to mycobacterial
vaccination or challenge (baseline SFU). Threshold values of 119 SFU
(mean+ 1.5 SD) for PPD-; 28 SFU (mean+ 2.0 SD) for CFP10-; and 40 SFU
(mean+ 2.0 SD) for ESAT6-specific SFU were selected to encompass the
95th percentile of SFU frequencies measured at baseline. Only responses
exceeding these thresholds were considered as positive. Antigen-specific
IFN-γ SFU profiles were plotted using Graphpad v7.0 (Graphpad Inc, USA)
and used to calculate area under the curve (AUC) values for comparison of
vaccination group median AUC by Mann–Whitney U test.
Whole blood intracellular cytokine staining (WB ICS) assay
In vitro stimulation. The method used to stimulate blood cells for ICS was
closely aligned with protocols applied in MTBVAC clinical trials conducted
by the South African Tuberculosis Vaccine Initiative (SATVI)15. In brief, WB
ICS was performed using 450 μl of sodium heparin (Sigma-Aldrich, UK)
anti-coagulated blood incubated for a total of 12 h with 0.25 μg/ml of anti-
CD28 and anti-CD49d co-stimulatory antibodies (both from BD Biosciences,
UK) and 1 μg/ml of selected M. tuberculosis peptides (TB Mega-pool
provided by C. Lindestam-Arlehamn, La Jolla Institute for Allergy and
Immunology, USA), 1 × 106 CFU/ml of MTBVAC (Biofabri, Spain), 5 μg/ml of
staphylococcus enterotoxin B (SEB) as a positive control (Sigma-Aldrich,
UK), or sterile phosphate buffer saline (PBS) as a negative control (Severn
Biotech, UK). Antigenic stimulation was initiated within 2 h of blood sample
collection and proceeded for 7 h in a 37 °C water bath before 50 μl of
A.D. White et al.
7
Published in partnership with the Sealy Institute for Vaccine Sciences npj Vaccines (2021) 4
plasma was removed from each sample and frozen at −80 °C as a resource
for future interrogation of secreted biomarkers. The protein transport
inhibitor Brefeldin-A (Sigma-Aldrich, UK) was added to the mixture at a
final concentration of 10 μg/ml, and the samples returned to incubation
conditions for a further 5 h. Following the completion of the incubation
period, EDTA solution (Sigma-Aldrich, UK) was added at a concentration of
2 mM to detach adherent cells. After 15 min, the sample was diluted 1:10 in
FACSlyse solution (BD Biosciences, UK) and incubated for 15min to remove
red blood cell contamination. Finally, the cellular fraction of the sample
was separated by centrifugation and resuspended in 1ml of cryosolution
consisting of 30% foetal calf serum (Labtech,UK), 20% DMSO and 50%
RPMI culture medium (both from Sigma-Aldrich, UK), before freezing under
a controlled cooling rate and cryopreservation in liquid nitrogen
vapour phase.
Samples were thawed in batches for flow cytometry analysis such that
all the samples from an individual animal were stained with antibodies and
analysed on the same occasion. The cryopreserved material was rapidly
thawed at 37 °C and washed twice by tenfold dilution in RPMI+ 1U/ml
DNase (Sigma-Aldrich, UK) followed by centrifugation. Cells were
permeabilised using BD cytofix/cytoperm reagent, washed and resus-
pended in 50 μl perm wash buffer (BD Biosciences, UK) for surface and
intracellular antibody staining. The cell surface and intracellular staining
mixture were prepared in Brilliant Staining buffer (BD Biosciences, UK) and
consisted of the following fluorochrome-conjugated antibodies: anti-CD3
AF700; anti-CD4 PerCP-Cy5.5; anti-CD161 Pe-Cy7; anti-IFN-γ FITC; anti-TNF-
α BUV395 (all from BD Biosciences, UK); anti-CD8 APC-Fire750; anti-Vα7.2
PE-Dazzle 594; anti-CD16 BV785; anti-γδ-TCR BV421; anti-IL-17 BV711; anti-
CD56 BV605 (all from Biolegend, UK); anti-IL-22 APC (Thermo Fisher
Scientific, UK) and anti-IL-2 PE (Miltenyi Biotech, UK). BD Compbeads (BD
Biosciences, UK) were labelled with the above fluorochromes for use as
compensation controls. Following antibody labelling, cells and beads were
washed by centrifugation and fixed in 4% paraformaldehyde solution
(Sigma-Aldrich, Gillingham, UK) prior to flow cytometric acquisition.
Flow cytometric acquisition and analysis. Flow cytometry data was
acquired using a five-laser LSRII Fortessa instrument (BD Biosciences,
Oxford, UK) and data were analysed using FlowJo (version 10.5.3 BD
Biosciences, UK) (Supplementary Fig. 8). Cell aggregates and debris were
excluded from the analysis using forward scatter-height (FSC-H) versus
forward scatter-area (FSC-A), followed by side scatter-height (SSC-H) versus
side scatter-area (SSC-A) plots. Cytokine-producing lymphocyte popula-
tions were then identified using a FSC-H versus SSC-A dot plot, followed by
sequential gating through CD3+, followed by CD4+, CD8+ or γδ-TCR+
gates for identification of the major T-cell populations, or CD3−, CD8+,
CD56+ and/or CD16+ NK cells, before individual cytokine gates to identify
IFN-γ, IL-2, IL-17, IL-22 and TNF-α producing populations. Polyfunctional
T cells were identified using Boolean gating combinations of individual
cytokine-producing CD4, CD8 or γδ T cells. The software package PESTLE
(version 1.8) was used for background subtraction to obtain antigen-
specific cytokine responses, and Graphpad (version 8.0.1) was used to
generate graphical representations of flow cytometry data (Graphpad
Software Inc, USA).
Necropsy
The necropsies were conducted either when the disease progressed to
meet the criteria set as a humane endpoint or 16 to 18 weeks after M.
tuberculosis aerosol challenge. Animals were anaesthetised, and clinical
data collected. Blood samples were taken prior to euthanasia by
intracardiac injection of a lethal dose of anaesthetic (Dolelethal, Vétoquinol
UK Ltd, 140 mg/kg). A post-mortem examination was performed immedi-
ately and gross pathological changes were scored using an established
system based on the number and extent of lesions present in the lungs,
spleen, liver, kidney and lymph nodes, as described previously29. Samples
of spleen, liver, kidneys and tracheobronchial, inguinal and axillary lymph
nodes were removed and sampled for quantitative bacteriology. The lung,
together with the heart and attached tracheobronchial and associated
lymph nodes, were removed intact. The lymph nodes were measured and
examined for lesions. These were fixed by intra-tracheal infusion with 10%
neutral buffered formalin (NBF) using a syringe and 13CH Nelaton catheter
(J.A.K. Marketing, York, UK). The catheter tip was inserted into each
bronchus in turn via the trachea; the lungs were infused until they were
expanded to a size considered to be normal inspiratory dimensions, and
the trachea ligated to retain the fluid. The infused lung was immersed in
10% NBF. In addition, samples of kidneys, liver, spleen, and sub clavicular,
hepatic, inguinal and axillary lymph nodes were fixed in 10% NBF.
Pathology studies
Gross examination following fixation. The lung lobes were sliced serially
(~5-mm intervals). Discrete and coalesced lesions were counted and
recorded, and the dimensions of the latter were measured. A tissue slice
containing obvious lesions (when present) was chosen from each lung
lobe. Where gross lesions were not visible, a sample was taken from a pre-
defined anatomical location from each lobe to establish consistency
between animals. Sections of LALN (those associated with the distal
trachea and bifurcation) and from extra-thoracic organs described
previously, were also fixed in formalin.
Histopathological examination. All samples were processed to paraffin
wax blocks using standard procedures, sectioned at ~4 μm, stained with
haematoxylin and eosin (H&E) and Ziehl-Neelsen (ZN) stains. Slides were
scanned digitally using ‘3D Histech’ slide scanner and proprietary
‘Caseviewer’ software used to capture, store and annotate digital images.
All gross and histopathological examinations were carried out by a
qualified veterinary pathologist blinded to the treatment group. Each slide
was evaluated for the presence of tuberculous lesions and AFBs. The TB-
associated lesions were recorded using the scoring system described by
Rayner et al.30. Briefly, six different types of granulomas were identified.
Types one (I), two (II) and three (III) were considered as “unorganised”
lesions, while types four (IV), five (V) and six (VI) were described as
“organised” granulomas. Type I was small, diffuse foci of macrophages and
lymphocytes with scattered neutrophils and eosinophils, lacking clearly
defined margins, infiltrate alveolar walls and extend into alveoli. Type II
lesions were composed of similar cell types as type I but were larger in size
and forming a more defined circumscribed focus of granulomatous
inflammation, frequently circular and with variably demarcated border.
Type III was as type II but with focal necrosis present, characterised by
nuclear pyknosis and karyorrhexis with the loss of cellular architecture.
Type IV was characteristically circumscribed granulomas consisting
primarily of macrophages admixed with neutrophils and other leucocytes,
with evidence of a few peripheral lymphocytes. Type V was organised
lesions exhibiting necrotic foci with degenerated neutrophils and type VI
were classic, largely well-demarcated, granulomas with central caseous
necrosis and a variable rim of lymphocytes. For each tissue section, the
total area of gross disease was calculated and the total number of
granulomas of each type were counted and recorded. Moreover, the total
number of AFBs were counted for each granuloma in the ZN-stained
sections from the lung and LALN.
Bacteriology
The spleen, kidneys, liver and tracheobronchial lymph nodes were sampled
for the presence of viable M. tuberculosis post-mortem, as described
previously20. Weighed tissue samples were homogenised in 2ml of sterile
water, then either serially diluted in sterile water prior to being plated, or
plated directly onto Middlebrook 7H11 OADC selective agar. Plates were
incubated for three weeks at 37 °C and resultant M. tuberculosis colonies
counted. Mean CFU counts from replicate tissue samples were used for
graphical presentation. The lower limit of detection for culture on plates
was five CFUs per mL of homogenate.
Statistical analyses
GraphPad Prism version 7.0 (GraphPad Software Inc, La Jolla, California,
USA) was used for all graphical data representations and statistical
analyses, these included: comparison of antigen-specific IFN-γ SFU
frequencies measured using the ex vivo ELISpot assay, frequencies of
specific cell subsets and multifunctional cell populations measured by flow
cytometry, differences in qualitative pathology scores and histopathology
granuloma severity scores, quantification of viable M. tuberculosis in
extrapulmonary tissues and comparisons of clinical parameters between
vaccination groups, using non-parametric Wilcoxon signed-rank or
Mann–Whitney U tests. Chi-squared (Χ2 tests were used to compare
differences between the vaccination groups in the proportion of
bacteriology tissue samples where viable M. tuberculosis CFU levels were
below the lower limit of detection of the assay and Cochran–Armitage
method Χ2 tests for the comparison of the frequency of granuloma severity
data. Disease progression between groups was compared using log-rank
survival analysis. Where applicable, all statistical analyses were conducted
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using two-tailed tests and P values are unadjusted for multiple
comparisons.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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